'Phase ii study' diaporamas de présentation

????????? ??? , M.S., RPh .

????????? ??? , M.S., RPh. ??. ???????? ?????? ???? ????????? ??????????. Quiz. How long will it take? Probability? Profit? vs. Cost? Luck vs. Effort?. Statistics. New Drugs Begin in the Laboratory , Discovering and Bringing One New Drug to the public

969 views • 66 slides

????????? ??? , M.S., RPh .

????????? ??? , M.S., RPh. ??. ???????? ?????? ???? ????????? ??????????. Quiz. How long will it take? Probability? Profit? vs. Cost? Luck vs. Effort?. Statistics. New Drugs Begin in the Laboratory , Discovering and Bringing One New Drug to the public

663 views • 66 slides

1.48k views • 47 slides

Cell density and cancer volume

580 views • 40 slides

Clinical and pharmacological background

Clinical and pharmacological background. Microtubule stabilizing (and destabilizing) agents have relevant role in the treatment of breast cancer (and other tumors) They are natural compounds discovered serendipitously or in large-scale screens from plant, microbial, and marine sources

709 views • 40 slides

Idiopathic Pulmonary Fibrosis Standards of Care & Investigational Therapies

523 views • 28 slides

Greetings from Rhode Island!

Greetings from Rhode Island!. 1. Rhode Island Disaster Initiative (RIDI) Program Overview. Grateful Thanks. Acknowledgment: "This material is based upon the work supported by the Office of Naval Research."

285 views • 28 slides

Hematology Highlights ASCO 2011

Hematology Highlights ASCO 2011. Don M Benson Jr MD PhD The Ohio State University Comprehensive Cancer Center. Overview. Acute leukemia Chronic lymphocytic leukemia Lymphoma Myeloma.

408 views • 27 slides

I-394 MnPASS : Phase I Results and Phase II Planning Study

I-394 MnPASS : Phase I Results and Phase II Planning Study. Optimizing Corridor Performance By Jim Kranig, P.E. Minnesota Department of Transportation. Presentation Outline. Project goals and innovations Performance update Evaluation results Phase II study elements Next steps.

359 views • 25 slides

Abstract ? 4532

DEFINITIVE CHEMORADIOTHERAPY (CRT) WITH FOLFOX 4 OR 5FU-CISPLATIN AS FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH INOPERABLE ESOPHAGEAL CANCER (IEC) : FINAL RESULTS OF A RANDOMIZED PHASE II STUDY.

332 views • 21 slides

Realizing value from leading Scandinavian life science research

Realizing value from leading Scandinavian life science research. Accelerator - At a glance. A life science group aiming to create and realize value Majority owner in 6 companies Business model aimed at commercialize life science projects Attractive target areas Large medical needs

273 views • 18 slides

Realizing value from leading Scandinavian life science research

Realizing value from leading Scandinavian life science research. Accelerator - At a glance. A life science group aiming to create and realize value Majority owner in 6 companies Business model aimed at commercialize life science projects Attractive target areas Large medical needs

182 views • 18 slides

The Targeted Therapy Continuum

313 views • 16 slides

1 Cortes JE et al. Proc ASH 2013;Abstract 494.

309 views • 12 slides

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Fowler NH et al. Proc ASH 2012; Abstract 901. Background.

219 views • 8 slides

Sekeres MA et al. Proc ASH 2010 ; Abstract 332.

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605). Sekeres MA et al. Proc ASH 2010 ; Abstract 332. Background.

83 views • 8 slides